drugset
drugset / Trial / NCT01917916

Single Rising Doses of BI 655064 in Healthy Chinese and Japanese Male Volunteers

NCT01917916 ↗

Phase 1 Completed 64 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Safety, tolerability, pharmacokinetics and pharmacodynamics of BI 655064 after single rising doses in healthy Asian male volunteers.

Timeline

Start
2013-08-05
Primary completion
2014-05-14
Completion
2014-05-14

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 655064 Monoclonal antibody 80 mg Subcutaneous
Subject BI 655064 Monoclonal antibody 120 mg Subcutaneous
Subject BI 655064 Monoclonal antibody 180 mg Subcutaneous
Subject BI 655064 Monoclonal antibody 240 mg Subcutaneous

Indications

No indication recorded.